

Hirata, Y., Okano, H., Nagai, R.	participate in vascular remodeling after mechanical injury.				
Sata, M., Fukuda, F., Tanaka, K., Kaneda, Y., Yashiro, H., Shirakawa, I.	The role of circulating precursors in vascular repair and lesion formation.	<i>J. Cell. Mol. Med.</i>	9	557-568	2005
Sata, M., Tanaka, K., Nagai, R.	Circulating Osteoblast-Lineage Cells.	<i>N. Engl. J. Med.</i>	353	737-738	2005
Saito K, Ishizaka N, Hara M, Matsuzaki G, Sata M, Mori I, Ohno M, Nagai R.	Lipid accumulation and transforming growth factor- β upregulation in the kidneys of rats administered angiotensin II.	<i>Hypertension</i>	46	1180-1185	2005
Yamamoto, T., Sata, M., Fukuda, D., Takamoto, S.	The angiotensin II type 1 receptor blocker candesartan attenuates graft vasculopathy.	<i>J Surg Res</i>	132	62-68	2006
Takeda R, Nishimatsu H, Suzuki E, Satonaka H, Nagata D, Oba S, Sata M, Takahashi M, Yamamoto Y, Terauchi Y, Kadowaki T, Kangawa K, Kitamura T, Nagai R, Hirata Y.	Ghrelin improves renal function in mice with ischemic acute renal failure.	<i>J Am Soc Nephrol</i>	17	113-121	2006
Yamazaki S, Miki K, Takayama T, Hasegawa K, Sata M, Midorikawa Y, Aburatani H, Makuuchi M.	Hepatic gene induction in murine bone marrow after hepatectomy.	<i>J Hepatol.</i>	44	325-333	2006.
Nishimura S, Yamashita H, Katoh M, Yamada KP, Sunagawa K, Saeki Y, Ohnuki Y, Nagai R, Sugiura S.	Contractile dysfunction of cardiomyopathic hamster myocytes is pronounced under high load conditions.	<i>J Mol Cell Cardiol.</i>	39	231-239.	2005

【平成18年度】

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	ページ	出版年
佐田政隆	骨髄由来細胞の役割	小川久雄編集	慢性冠動脈疾患の臨床	中山書店	東京	48-53	2006

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yamamoto, T., Sata, M., Fukuda, D., Takamoto, S.	The angiotensin II type 1 receptor blocker candesartan attenuates graft vasculopathy.	J Surg Res	132	62-68	2006
Takeda R, Nishimatsu H, Suzuki E, Satonaka H, Nagata D, Oba S, Sata M, Takahashi M, Yamamoto Y, Terauchi Y, Kadowaki T, Kangawa K, Kitamura T, Nagai R, Hirata Y.	Ghrelin improves renal function in mice with ischemic acute renal failure.	J Am Soc Nephrol,	17	113-121	2006
Yamazaki S, Miki K, Takayama T, Hasegawa K, Sata M, Midorikawa Y, Aburatani H, Makuuchi M.	Hepatic gene induction in murine bone marrow after hepatectomy	J Hepatol.	44	325-333	2006
Tateishi K, Ohta M, Guleng B, Kanai F, Tanaka Y, Asaoka Y, Jazag A, Imamura J, Imamura T, Ijichi H, Ikenoue T, Kawakami T, Fukushima Y, Washida M, Sata M, Miyagishi M, Taira K, Yoshida H, Kawabe T, Omata M.	TRAIL-induced cell death cooperates with IFN-gamma activation in the graft-versus-tumor effect against colon tumors.	Int J Cancer.	118	2237-2246	2006
Sainz, J., Sata, M.	Targeting bone marrow to treat vascular disease	Cardiovasc Res	70	3-5	2006

	ases: Accelerated vascular healing by colony stimulating factor.				
Sata, M.	The role of circulating vascular progenitors in angiogenesis, vascular healing and pulmonary hypertension: Lessons from animal models.	Arterioscler Thromb Vasc Biol.	26	1008-1014	2006
Sainz, J., Sata, M	Maintenance of Vascular Homeostasis by Bone Marrow-derived Cells.	Arterioscler Thromb Vasc Biol.	26	1196-1197	2006
Nishimura, S., Nagai, S., Sata, M., Katoh, M., Yamashita, H., Saeki, Y., Nagai, R., Sugiura, S.	Expression of green fluorescent protein impairs the force-generating ability of isolated rat ventricular cardiomyocytes	Mol Cell Biochem.	286	59-65	2006
Ohtani, K., Egashira, K., Ihara, Y., Nakano, K., Funakoshi, K., Zhao, G., Sata, M., Sunagawa, K. .:	Angiotensin II Type 1 Receptor Blockade Attenuates In-Stent Restenosis by Inhibiting Inflammation and Progenitor Cells.	Hypertension.	48	664-670	2006
Abe, M., Sata, M., Suzuki, E., Takeda, R., Takahashi, M., Nishimatsu, H., Nagata, D., Kangawa, K., Matsuo, H., Nagai, R., Hirata Y.	Effects of adrenomedullin on acute ischemia-induced collateral development and mobilization of bone marrow-derived cells.	Clin Sci (Lond).	111	381-387	2006
Yoshioka M, Yuasa S, Matsumura K, Kimura K, Shiomi T, Ki	Chondromodulin-I maintains cardiac valvular	Nat Med.	12	1151-1159	2006

mura N, Shukunami C, Okada Y, Mukai M, Shin H, Yozu R, Sata M, Ogawa S, Hiraki Y, Fukuda K.	function by preventing angiogenesis.				
Hanajiri K, Maruyama T, Kaneko Y, Mitsui H, Watanabe S, Sata M, Nagai R, Kashima T, Shibahara J, Omata M, Matsumoto Y.	Microbubble-induced increase in ablation of liver tumors by high-intensity focused ultrasound.	Hepatol Res.	36	308-314	2006
Sahara M, Takahashi T, Imai Y, Nakajima T, Yao A, Morita T, Hirata Y, Nagai R.	New insights in the treatment strategy for pulmonary arterial hypertension.	Cardiovasc Drugs Ther	20	377-386	2006
Shimizu T, Takeda N, Takahashi M, Imai Y, Ishizaka N, Hirata Y, Nagai R.	Subarachnoid hemorrhage from mycotic aneurysms.	Intern Med.	45	1189-1190.	2006
Sahara M, Takahashi T, Morita T, Yao A, Nagashima Y, Hirata Y, Nagai R.	Three-vessel coronary artery disease complicated with congestive heart failure in a highly aged patient with tetralogy of Fallot having undergone palliative surgeries.	Intern Med.	45	1147-1151	2006
Sakamoto A, Okamoto K, Ishizaka N, Tejima K, Hirata Y, Nagai R.	(18)F-fluorodeoxyglucose positron emission tomography in a case of retroperitoneal fibrosis.	Int Heart J.	47	645-650	2006
Matsumura T, Matsumoto A, Ohno M, Suzuki S, Ohta M, Suzuki E, Takenaka K, Hirata Y, Fujita T, Nagai R.	A case of cholesterol embolism confirmed by skin biopsy and successfully treated with statins and steroids.	Am J Med Sci.	331	280-283	2006

【平成19年度】

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	ページ	出版年
田中君枝、 佐田政隆	B慢性心不全の治療 21. 再生医療にエビデンスはあるのか？	三田村秀雄、山科章、川名正敏、桑島巖編集	EBM循環器疾患の治療 2008-2009	中学医学社	東京	356-361	2007
佐田政隆	薬剤による血管再生 血管の再生—	森下竜一編集	血管再生医学の夜明け：近づく実用化	真興交易(株) 医学出版部	東京	118-129	2008
Sata, M., Walsh, K.	Contribution of circulating progenitor cells to vascular repair and lesion formation.	H. J. Ducker, E. G. Nabel, P. W Serruys eds.	<i>Essentials of Restenosis.</i>	Humana Press Inc.	Totowa, N.J.	pp. 185-197.	2007

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Sumi, M., Sata, M., Toya, N., Yanaga, K., Ohki, T., Nagai, R.	Transplantation of adipose stromal cells, but not mature adipocytes, augments ischemia-induced angiogenesis.	Life Sci.	80	559-565	2007
Wakayama, K., Shimamura, M., Sata, M., Sato, N., Kawakami, K., Fukuda, H., Tomimatsu, T., Ogihara, T., Morishita, R.	Quantitative measurement of neurological deficit after mild (30 min) transient middle cerebral artery occlusion in rats.	Brain Res.	1130	181-187	2007
Sainz, J., Sata, M.	CXCR4, a key modulator of vascular progenitor cells.	Arterioscler Thromb Vasc Biol.	27	263-265	2007

Sahara, M., Sata, M., Morita, T., Nakamura, K., Hirata, Y., Nagai, R.	Diverse contribution of bone marrow-derived cells to vascular remodeling associated with pulmonary arterial hypertension and arterial neointimal formation.	Circulation	115	509-517	2007
Inoue, T., Sata, M., Hikichi, Y., Sohma, R., Fukuda, D., Uchida, T., Shimizu, M., Komoda, H., Node, K.	Mobilization of CD34-Positive bone marrow-derived cells after coronary stent implantation : impact on restenosis.	Circulation	115	553-561	2007
Sumi, M., Sata, M., Miura, S. I., Rye, K.A., Toya, N., Kanaoka, Y., Yanaga, K., Ohki, T., Saku, K., Nagai, R.	Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis.	Arterioscler Thromb Vasc Biol.	27	813-818.	2007
Kojima, I., Tanaka, T., Inagi, R., Kato, H., Yamashita, T., Sasaki, A., Ohneda, O., Takeda, N., Sata, M., Miyata, T., Fujita, T., Nangaku, M	Protective role of HIF-2 α against ischemic damage and oxidative stress in the kidney.	J Am Soc Nephrol.	18	1218 -1226	2007
Suzuki, T., Nishi, T., Nagino, T., Sasaki, K., Aizawa, K., Kanda, N., Sawaki, D., Munemasa, Y., Matsumura, T., Muto, S., Sata, M., Miyagawa, K., Horikoshi, M., Nagai, R.	Functional interaction between the transcription factor Kruppel-like factor 5 and poly(ADP-ribose) polymerase-1 in cardiovascular apoptosis.	J Biol Chem.	282	9895 -9901	2007
Sumi, A., Sata, M., Hashimoto, A., Imaizumi, T., Yanaga, K., Ohki, T., Mori, T., Nagai, R.	OPC-28326, a selective femoral arterial vasodilator, augments ischemia induced angiogenesis.	Biomed Pharmacother.	61	209-215	2007
Shirakawa, I., Sata, M., Saiura, A., Kaneda, Y., Yashiro, H.,	Atorvastatin attenuates transplant-associated coronary arteriosclerosis.	Biomed Pharmacother.	61.	154-159	2007

Hirata, Y., Makuuchi, M., Nagai, R.	clerosis in a murine model of cardiac transplantation.	other.			
Nakamura, K., Sata, M., Iwata, H., Sakai, Y., Hirata, Y., Kugiyama, K., Nagai, R.	A synthetic small molecule, ONO-1301, enhances endogenous growth factor expression and augments angiogenesis in ischemic heart	Clin Sci (Lond).	112	607-616	2007
Aihara, K., Azuma, H., Akaike, M., Ikeda, Y., Sata, M., Takamori, N., Yagi, S., Iwase, T., Sumitomo, Y., Kawano, H., Yamada, T., Fukuda, T., Matsumoto, T., Sekine, K., Sato, T., Nakamichi, Y., Yamamoto, Y., Yoshimura, K., Watanabe, T., Nakamura, T., Oomizu, A., Tsukada, M., Hayashi, H., Sudo, T., Kato, S., Matsumoto, T.	Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice.	J. Clin. Invest.	117	1514-1526	2007
Tanaka, K., Sata, M.	Therapeutic application of bone marrow-derived progenitor cells for vascular diseases: Magic bullets having the good without the bad.	Int. J. Gerontol.	1.	10-21	2007
Shimamura, M., Sato, N., Sata, M., Wakayama, K., Ogihara, T., Morishita, R.	Expression of hepatocyte growth factor and c-Met after spinal cord injury in rats.	Brain Res.	1151	188-194	2007
Iwata, H., Sata, M.	Potential contribution of bone marrow-derived precursors to vascular repair and lesion formation: lessons from animal models of vascular diseases.	Frontiers in Bioscience	12	4157-4167	2007
Yamada, T., Kondo, T., Numaguchi, Y., Tsuzuki, M., Matsuura, T., Manabe, I., Sata, M.	Angiotensin II receptor blocker inhibits neointimal hyperplasia through regulation of sm	Arterioscler Thromb Vasc Biol.	11	2363-2369.	2007

Nagai, R., Murohara, T.	ooth muscle-like progenitor cells.				
Fukuda, D., <u>Sata, M.</u>	Renin-angiotensin system: a potential modulator of endothelial progenitor cells.	Hypertens Res.	30	1017-1018	2007
Shimamura, M., Sato, N., <u>Sata, M.</u> , Kurinami, H., Takeuchi, D., Wakayama, K., Hayashi, T., Iida, H., Morishita, R.	Delayed post-ischemic treatment with fluvastatin improved cognitive impairment after stroke in rats.	Stroke.	38	3251-3258	2007
Fukuda, D., <u>Sata, M.</u> , Ishizaka, N., Nagai, R.	A critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E deficient mice.	Arterioscler Thromb Vasc Biol.	28	90-96	2008
Sainz, J., <u>Sata, M.</u>	Open sesame! CXCR4 blockade recruits neutrophils into the plaque	Circ Res.	102	154-156	2008
Tanaka, K., <u>Sata, M.</u> , Natoti, T., Kim-Kaneyama, J-R., Nose, K., Shibamura, M., Hirata, H., Nagai, R.	Circulating progenitor cells contribute to neointimal formation in non-irradiated chimeric mice.	FASEB J	22	428-436	2008
Huang, P-H., Sata, M., Nishimatsu, H., Sumi, M., Hirata, Y., Nagai, R.	Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice.	Biomed Pharmacother.	62	46-52	2008
Matsumoto, M., <u>Sata, M.</u> , Fukuda, D., Tanaka, K., Soma, M., Hirata, Y., Nagai, R.	Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in ApoE-deficient mice.	Atherosclerosis	197	524-533.	2008
Shimazaki, M., Nakamura, K., Kii, I. Kashima, T., Amizuka, N., Li, M., Fukuda, K., Nishiyama, T., Kitajima, S., Saga, Y., Fukayama, M., Sata, M.,	Periostin is essential for cardiac healing after acute myocardial infarction.	J Exp. Med.	205	295-303	2008.

Kudo, A.					
Kumano, K., Masuda, S., <u>Sata, M.</u> , Saito, T., Lee, S.Y., Sakata-Yanagimoto, M., Tomita, T., Iwatsubo, T., Natsugari, H., Kurokawa, M., Ogawa, S., Chiba, S.	Both Notch1 and Notch2 contribute to the regulation of melanocyte homeostasis.	Pigment Cell Melanoma Res	21:	70-78.	2008.
Imaizumi, S., Miura, S., Nakamura, K., Kiya, Y., Uehara, Y., Zhang, B., Matsuo, Y., Urata, H., Ideishi, M., Rye, K. A., Sata, M., Saku, K.	Anti-arrhythmogenic effect of reconstituted high-density lipoprotein against ischemia/reperfusion in rats.	J Am Coll Cardiol.		in press	
Enomoto, S., <u>Sata, M.</u> , Fukuda, D., Nakamura, K., Nagai, R.	Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice.	Biomed Pharmacother.		in press	
Fukuda, D., <u>Sata, M.</u>	Role of bone marrow renin-angiotensin system in the pathogenesis of atherosclerosis.	Pharmacol Ther.		in press	
Tanaka, K., <u>Sata, M.</u>	Potential role of statins in re-endothelialization	Immun., Endoc. & Metab. Agents in Med. Chem.		in press	

研究成果の刊行物・別刷

A synthetic small molecule, ONO-1301, enhances endogenous growth factor expression and augments angiogenesis in the ischaemic heart

Kazuto NAKAMURA*†, Masataka SATA*‡, Hiroshi IWATA*, Yoshiki SAKAI§, Yasunobu HIRATA*, Kiyotaka KUGIYAMA† and Ryozo NAGAI*

*Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan, †Second Department of Internal Medicine, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, 1110 Shimokato, Nakakoma-gun, Yamanashi, 409-3898, Japan, ‡Department of Advanced Clinical Science and Therapeutics, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan, and §Ono Pharmaceutical Company Ltd, 2-1-5 Doshomachi, Chuo-ku, Osaka 541-8526, Japan

A B S T R A C T

It has been shown previously that administration of angiogenic growth factors as genes or proteins can augment collateral growth in ischaemic tissues. In the present study, we have investigated the effect of ONO-1301, a synthetic prostacyclin agonist with thromboxane-synthase-inhibitory activity, on expression of endogenous growth factors and angiogenesis. ONO-1301 induced secretion of HGF (hepatocyte growth factor) and VEGF (vascular endothelial growth factor) from cultured normal human dermal fibroblasts in a dose-dependent manner. Dibutyryl cAMP, an analogue of cAMP, and forskolin, an adenylate cyclase activator, mimicked the effect of ONO-1301. Conversely, Rp-cAMP (adenosine 3',5'-cyclic monophosphorothioate), an inhibitor of cAMP, partially inhibited the effect of ONO-1301, suggesting that cAMP mediated the effect of ONO-1301 in up-regulating the expression of HGF and VEGF, at least in part. ONO-1301 promoted tube-like formation by HUVECs (human umbilical vein endothelial cells) when co-cultured with fibroblasts, and the angiogenic effect of ONO-1301 was abrogated by administration of a neutralizing antibody against HGF or VEGF. To generate a slow-releasing form of ONO-1301, ONO-1301 was mixed with poly(DL-lactic-co-glycolic acid). The slow-releasing form of ONO-1301 was injected directly into the ischaemic myocardium of mice immediately after ligation of the left anterior descending artery. The slow-releasing form of ONO-1301 up-regulated HGF and VEGF expression and increased capillary density in the border zone (342.7 ± 29.7 capillaries/mm² in controls compared with 557.2 ± 26.7 capillaries/mm² in treated animals; $P < 0.01$) at 7 days. The slow-releasing form of ONO-1301 ameliorated left ventricular enlargement after 28 days and improved survival rate. In conclusion, our results indicate that ONO-1301 up-regulated endogenous growth factors and promoted angiogenesis in response to acute ischaemia. Therefore ONO-1301 might have a therapeutic potential in treating ischaemic diseases.

Key words: angiogenesis, cardiovascular system, hepatocyte growth factor (HGF), ischaemia, prostacyclin, regenerative medicine, vascular endothelial growth factor (VEGF).

Abbreviations: EBM, endothelial growth medium; FBS, fetal bovine serum; FS, fractional shortening; HASMC, human aortic smooth muscle cell; HGF, hepatocyte growth factor; HUVEC, human umbilical vein endothelial cell; LV, left ventricular; LVEDD, LV end-diastolic diameter; LVESD, LV end-systolic diameter; MI, myocardial infarction; NHDF, normal human dermal fibroblast; PG, prostaglandin; PLGA, poly(DL-lactic-co-glycolic acid); Rp-cAMP, adenosine 3',5'-cyclic monophosphorothioate; RT-PCR, reverse transcriptase-PCR; SR-ONO, slow-releasing form of ONO-1301; VEGF, vascular endothelial growth factor.

Correspondence: Dr Masataka Sata, at the Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan (email msata-circ@umin.net).

INTRODUCTION

Therapeutic angiogenesis has emerged as a promising therapy to treat ischaemic cardiovascular diseases [1]. Administration of growth factors as genes or recombinant proteins has been shown to significantly augment collateral growth in ischaemic tissues [2]. Recent evidence suggests that transplantation of endothelial progenitor cells or total bone marrow cells augments collateral development of ischaemic tissues [3]. As the number of incorporated cells with an endothelial phenotype in ischaemic tissues is generally quite low [4], it was hypothesized that the release of pro-angiogenic factors may mediate the efficacy of autologous cell transplantation [5]. Thus supplementation of angiogenic cytokines may represent a standard strategy in therapeutic angiogenesis. Although it remains to be determined which factor(s) would be the most efficient for clinical use [6], it has been suggested that a combination of several cytokines might be more effective [7].

PGs (prostaglandins) consist of a variety of bioactive substances that play an important role in maintaining local tissue homeostasis and evoking inflammatory responses. Interestingly, some PGs and their analogues have been shown to stimulate expression of growth factors or cytokines *in vitro* and *in vivo* [8–12]. Matsumoto et al. [8] reported that HGF (hepatocyte growth factor) production by fibroblasts was strongly induced by PGE₁ and prostacyclin, but only slightly by PGE₂ and PGD₂, through transcriptional activation of the HGF gene. It was hypothesized that PGE₁ and prostacyclin, rapidly synthesized after tissue injury, may have a role in tissue repair by inducing HGF expression [8]. In fact, exogenous administration of prostacyclin or its analogues has been shown to protect ischaemic myocardium *in vivo* [13,14]. Indeed, prostacyclin is the major PG released from the ischaemic heart [15]. Prostacyclin analogues have been reported to induce VEGF (vascular endothelial growth factor) expression and enhance angiogenesis *in vivo* in a mouse cornea model [16].

ONO-1301 is a synthetic prostacyclin agonist lacking the typical prostanoid structures, including a five-membered ring and allylic alcohol [17–20]. Prostacyclin and its analogues are not stable *in vivo*, because 15-hydroxyPG dehydrogenase metabolizes their prostanoid structures. In contrast, ONO-1301 is chemically and biologically stable because of the absence of prostanoid structures. Notably, ONO-1301 has thromboxane-synthase-inhibitory activity, because of the presence of a 3-pyridine radical. ONO-1301 exerts long-lasting prostacyclin activity when administered *in vivo* [17–20].

In the present study, we have investigated the effect of ONO-1301 on expression of endogenous growth factors and angiogenesis. ONO-1301 successfully up-regulated the expression of endogenous VEGF and HGF *in vitro* and *in vivo*. Local administration of a slow-releasing form of ONO-1301 augmented angiogenesis and

ameliorated LV (left ventricular) enlargement after acute MI (myocardial infarction). Our findings suggest that up-regulation of endogenous growth factors with a small molecule might be useful in therapeutic angiogenesis.

MATERIALS AND METHODS

Animals

Adult male CD1 inbred mice were purchased from SLC Japan [21]. Blood pressure and pulse rate of each mouse were measured with a tail-cuff system (BP-98A; Softron) in conscious animals. In each animal, the mean value of three measurements was used for comparison. All experimental procedures and protocols were approved by the Animal Care and Use Committee of the University of Tokyo and complied with the Guide for the Care and Use of Laboratory Animals (NIH publication No. 86-23, revised 1985).

ONO-1301 and generation of its slow-releasing form

ONO-1301 was synthesized by ONO Pharmaceutical Co. Ltd as described previously [17–20]. A slow-releasing form of ONO-1301 (SR-ONO) was generated by polymerizing ONO-1301 with PLGA [poly(DL-lactic-co-glycolic acid)]. Briefly, ONO-1301 (5 mg) was mixed with 100 mg of PLGA (*M_n*, 20000; Wako) in 0.1% polyvinyl alcohol (1:1 molar ratio of PLGA/glycolic acid). Pellets were washed in distilled water several times and freeze-dried. Particle size of SR-ONO was approx. 25–30 μm in diameter, as determined by a Coulter counter. The releasing rate of ONO-1301 PLGA in 0.2% Tween 80/sodium phosphate buffer was determined by measuring residual ONO-1301 in the pellets.

Measurement of growth factors produced from cultured human fibroblasts

NHDFs (normal human dermal fibroblasts), purchased from Kurabo, were cultured on 48-well plates in DMEM (Dulbecco's modified Eagle's medium; Sigma) containing 10% (v/v) FBS (fetal bovine serum). Cells were serum-starved for 24 h and were cultured in the absence or presence of ONO-1301 (0.01–1 $\mu\text{mol/l}$) for 72 h. Dibutyl cAMP (Sigma), forskolin (Sigma) or Rp-cAMP (adenosine 3',5'-cyclic monophosphorothioate; Calbiochem) was added to the medium at the concentrations indicated ($n=3$ for each group). HUVECs (human umbilical vein endothelial cells), purchased from Cambrex, were cultured on 48-well plates in EBM (endothelial growth medium; Cambrex) containing 2% (v/v) FBS and endothelial cell growth supplements. HUVECs were serum-starved for 24 h and were cultured in EBM with 0.2% (v/v) FBS in the absence or presence of ONO-1301 (1 $\mu\text{mol/l}$) for 72 h ($n=3$ for each group). HASMCs (human aortic smooth muscle cells), purchased

from Kurabo, were cultured on 48-well plates in human smooth muscle cell growth medium (HuMedia-SG2; Kurabo) containing 5% (v/v) FBS and smooth muscle cell growth supplements. HASMCs were serum-starved for 24 h and were cultured in HuMedia-SG2 with 0.5% (v/v) FBS in the absence or presence of ONO-1301 (1 $\mu\text{mol/l}$) for 72 h ($n = 3$ for each group). Supernatants were harvested to measure concentrations of VEGF and HGF by ELISA (Quantikine; R&D Systems). Total RNA was extracted at 6 h after stimulation. Cells from passages 4–7 were used throughout the study.

Measurement of angiogenic activity *in vitro*

An *in vitro* angiogenesis kit (KZ-1000; Kurabo), consisting of a two-dimensional co-culture system of HUVECs/NHDFs on a 24-well plate, was used according to the manufacturer's instructions [22]. Cells were cultured in the absence or presence of ONO-1301 (0.1 $\mu\text{mol/l}$), a neutralizing anti-(human HGF) antibody (10 $\mu\text{g/ml}$; generously given by Dr George F. Vande Woude, Laboratory of Molecular Oncology, Van Andel Institute, Grand Rapids, MI, U.S.A.) [23] and a neutralizing monoclonal anti-(human VEGF) antibody (5 $\mu\text{g/ml}$; mouse IgG2B, clone 26503; R&D Systems), which recognizes human VEGF₁₆₅ and VEGF₁₂₁. Human recombinant VEGF₁₆₅ (KZ-1300; Kurabo) and human recombinant HGF (294-HG; Kurabo) were used as positive controls in the tube-formation assays. Suramin (Kurabo), an antitrypanosomal agent, was used as an inhibitor of angiogenesis [24]. At 11 days, cells were fixed with 10% formalin and stained using an anti-CD31 antibody. The length of CD31-positive endothelial cells of tube-like structures was quantified in five random high-power fields ($\times 40$ magnification) in a blinded fashion using an image analysing system (Kurabo). All assays were performed in triplicate.

Injection of SR-ONO into ischaemic myocardium

MI was induced in 8–10-week-old male CD-1 mice, weighing 35–40 g, by ligating the left anterior descending coronary artery, as described previously [25]. Briefly, mice were anaesthetized by intraperitoneal injection of pentobarbital (50 mg/kg of body weight). A 24-gauge polyethylene tube was inserted into the trachea and mechanical ventilation was provided by a rodent ventilator (SAR-830; CWE). The chest was opened and the heart was exposed. The left descending coronary artery was ligated by 7-0 nylon suture. Immediately after ligation, 2 mg of SR-ONO ($n = 31$), suspended in 50 μl of normal saline with 0.2% Tween 80, was injected directly into the anterior and lateral myocardium around the ischaemic border zone. A total of 2 mg of PLGA microspheres containing no ONO-1301 ($n = 29$) was injected as a

control. During the study period of 4 weeks, cages were inspected daily for survival analysis after MI. A neutralizing polyclonal goat anti-(mouse VEGF) antibody (0.0025 $\mu\text{g/kg}$ of body weight; R&D system), which recognizes mouse VEGF₁₆₄ and VEGF₁₂₀, or normal goat IgG (0.025 $\mu\text{g/kg}$ of body weight) was administered intraperitoneally at 0, 3, 5 and 7 days.

Echocardiography

Echocardiographic studies were performed under anaesthesia with pentobarbital (50 mg/kg of body weight) before surgery and at 1 and 28 days after MI [26]. An echocardiography system (EnVisor M2540A; Philips Medical System) was used with a dynamically focused 15 MHz linear-array transducer with a depth setting of 1.5 cm. The resolution provided by 15 MHz linear-array transducers has been reported to be high enough to measure LV diameter in a mouse heart beating at a high rate [27]. Two-dimensional images and M-mode tracings were recorded from the short-axis view at the high papillary muscle level. Care was taken not to apply too much pressure to the chest wall. Measurements were done for at least ten beats in a blinded fashion and repeated twice. LVEDD (LV end-diastolic diameter) and LVESD (LV end-systolic diameter) were measured. FS (fractional shortening) was calculated using the following equation: $\text{FS} (\%) = (\text{LVEDD} - \text{LVESD}) / \text{LVEDD} \times 100$.

Histological analysis

For histological analysis, mice were killed by intraperitoneal injection of an overdose of sodium pentobarbital at 7 or 28 days. The hearts were carefully removed and fixed with 10% neutral formalin by perfusion fixation. Fixed hearts were cut into three transverse sections from the ligated site of left coronary artery to the apex and embedded in paraffin. Sections (5 μm) were deparaffinized and stained with H&E (haematoxylin and eosin). Immunohistochemistry was performed as described previously [28]. The hearts were fixed overnight in methanol and embedded in paraffin. Sections (5 μm) were deparaffinized and incubated with a rat monoclonal antibody against murine CD31 (clone MEC13.3; BD PharMingen). Antibody binding was visualized using avidin-biotin and the Vector Red chromogenic substrate (Vector Laboratories), followed by counterstaining with haematoxylin. Capillaries were identified by positive staining for anti-CD31 antibody and morphology. The number of capillaries/ mm^2 was counted in regions with transversely sectioned myocytes in the border (peri-infarct) zone. Three or four fields in the border zone per section were analysed for each mouse (a total of 10–12 fields/heart) at $\times 200$ magnification [29,30]. Additional sections were counterstained with haematoxylin.

RT-PCR (reverse transcriptase-PCR)

Total RNA was prepared from both ischaemic and non-ischaemic myocardium using RNA Bee (Tel-Test) [31]. RT-PCR was performed as described previously [31]. First-strand cDNA was synthesized from 1 µg of total RNA, using oligo-(dT)₂₀ primer and MMLV (Moloney-murine-leukaemia virus)-derived reverse transcriptase (ReverTra Ace-α; Toyobo). A portion (1/20) of the reaction mixture was used as a template for PCR amplification. The mouse VEGF primers, 5'-GCCGGCCTGCCCTGCAGTC-3' (sense) and 5'-TCACCGCCTTGGCTTGTCAC-3' (antisense), yielded products of 716 bp (VEGF₁₈₈), 644 bp (VEGF₁₆₄) and 512 bp (VEGF₁₂₀). PCR reactions were carried out for 30 cycles with 1 min of denaturation at 94°C, 1 min of annealing at 65°C and 1.5 min of extension at 72°C, followed by 10 min of final extension. The mouse HGF primers, 5'-GCCGGCCTGCCCTGCAGTC-3' (sense) and 5'-TCACCGCCTTGGCTTGTCAC-3' (antisense), yielded a product of 423 bp (HGF). PCR reactions were carried out for 30 cycles with 1 min of denaturation at 94°C, 1 min of annealing at 55°C and 1.5 min of extension at 72°C, followed by 10 min of final extension [32]. The human VEGF primers, 5'-GGACATCTTCCAGGAGTA-3' (sense) and 5'-TGCAACGAGAGTCTGTGT-3' (antisense), yielded products of 413 bp and 341 bp. PCR reactions were carried out for 30–35 cycles with 30 s of denaturation at 94°C, 30 s of annealing at 60°C and 30 s of extension at 72°C, followed by 10 min of final extension. The human HGF primers, 5'-ATGCTCATGGACCCTGGT-3' (sense) and 5'-GCCTGGCAAGCTTCATTA-3' (antisense), yielded a product of 423 bp (HGF). PCR reactions were carried out for 30 cycles with 30 s of denaturation at 94°C, 30 s of annealing at 60°C and 1 min of extension at 72°C, followed by 10 min of final extension.

Statistics

All values are means ± S.E.M. Multiple comparisons were performed by one-way ANOVA with Fisher's post-hoc comparison. Survival analysis was performed by Kaplan-Meier analysis and evaluated by log-rank test. A value of $P < 0.05$ was considered to be statistically significant.

RESULTS

Effect of ONO-1301 on HGF and VEGF secretion

NHDFs were cultured on 48-well plates in the absence or presence of ONO-1301. ONO-1301 (1 µmol/l) increased the concentration of HGF and VEGF in the medium in a time-dependent manner, with a maximum response being obtained after 72 h (results not shown). Treatment with ONO-1301 (0.01–1 µmol/l) for 72 h increased HGF and VEGF concentrations in a dose-

dependent manner (Figures 1A and 1B). Dibutyryl cAMP (0.5 mmol/l), an analogue of cAMP, and forskolin (1 µmol/l), an adenylate cyclase activator, mimicked the effect of ONO-1301 (Figures 1C and 1D). Rp-cAMP (0.5 mmol/l), a cAMP inhibitor, partially inhibited the effect of ONO-1301 (Figure 1E). These results suggested that cAMP, at least in part, mediated the effect of ONO-1301 in up-regulating HGF. When a neutralizing anti-HGF antibody was added, ONO-1301 failed to up-regulate VEGF expression in fibroblasts, suggesting that HGF may mediate ONO-1301-induced stimulation of VEGF production (Figure 1F). Furthermore, to investigate the effect of ONO-1301 on growth factor secretion in other cell types, the effect of ONO-1301 on HUVECs and HASMCs was examined. Up-regulation of HGF or VEGF was not detected in ONO-1301-treated HUVECs as determined by ELISA (Figures 1G and 1H) or RT-PCR (results not shown). On the other hand, HASMCs produced HGF and VEGF abundantly, and ONO-1301 slightly, but significantly, up-regulated HGF secretion (Figure 1G).

Effect of ONO-1301 on *in vitro* angiogenesis

The angiogenic activity of ONO-1301 *in vitro* was evaluated using a two-dimensional co-culture system of HUVECs and NHDFs. ONO-1301 enhanced tube-like formation by HUVECs (Figure 2A). The angiogenic activity of ONO-1301 was comparable with that of VEGF or HGF. The angiogenic effect of ONO-1301 was reduced by administration of neutralizing anti-HGF or anti-VEGF antibodies. These findings suggested that the favourable effect of ONO-1301 on angiogenesis *in vitro* was mediated, at least in part, by up-regulation of HGF and VEGF.

Effect of ONO-1301 on endogenous growth factor expression in ischaemic myocardium

To deliver ONO-1301 locally and chronically, ONO-1301 was polymerized with PLGA to generate SR-ONO. The *in-vitro*-releasing test revealed that ONO-1301 was released continuously from SR-ONO within 12–14 days (Figure 3A). When the effect of PLGA and SR-ONO on growth factor secretion was tested, PLGA had no effect on HGF and VEGF expression (Figure 3B), whereas SR-ONO up-regulated secretion of both growth factors (Figure 3B). The angiogenic effect of ONO-1301 *in vivo* was evaluated by injecting SR-ONO into ischaemic myocardium immediately after ligation of the left anterior descending artery. No systemic effects, including those on blood pressure and heart rate, were observed following the local injection of SR-ONO into the heart. Expression of HGF and VEGF was analysed by RT-PCR in ischaemic and non-ischaemic areas at 7 days




Figure 1 Effect of ONO-1301 on HGF and VEGF production

(A and B) NHDFs were cultured in the absence or presence of ONO-1301 (0.01–1 μ mol/l) for 72 h. (C and D) NHDFs were cultured on a 48-well plate in the absence or presence of ONO-1301 (0.1 μ mol/l), dibutyryl cAMP (0.5 mmol/l) and forskolin (1 μ mol/l) for 72 h. (E) NHDFs were cultured with vehicle and ONO-1301 alone (1 μ mol/l) or in combination with Rp-cAMP (0.5 nmol/l) for 72 h. (F) NHDFs were cultured with vehicle and ONO-1301 alone (1 μ mol/l) or in combination with a neutralizing anti-HGF antibody (α HGF; 20 μ g/ml) for 72 h. (G and H) HUVECs and HASMCs were cultured in the absence or presence of ONO-1301 (1 μ mol/l) for 72 h. Following treatment, HGF (A, C, E and G) and VEGF (B, D, F and H) concentrations in the supernatants were determined by ELISA. In each panel, values are means \pm S.E.M. of two or three replicate measurements. * P < 0.05.

after MI (Figure 3C). HGF mRNA was down-regulated in the ischaemic myocardium treated with vehicle, and SR-ONO partially restored the expression. VEGF expression was not detected in the non-ischaemic myocar-

dium, but endogenous VEGF expression was slightly up-regulated in the ischaemic myocardium treated with vehicle. SR-ONO up-regulated VEGF expression further in ischaemic myocardium (Figure 3C).




Figure 2 Promotion of *in vitro* tube formation by ONO-1301

(A) *In vitro* angiogenic activity of ONO-1301 was evaluated in the absence or presence of ONO-1301 (0.1 μmol/l), a neutralizing anti-(human HGF) antibody (αHGF; 10 μg/ml) and a neutralizing anti-(human VEGF) antibody (αVEGF; 5 μg/ml). At 11 days, cells were fixed with 10% formalin and stained using an anti-CD31 antibody. (B) Length of CD31-positive endothelial cells with tube-like structures was quantified in five random high-power fields (× 40 magnification) in a blinded fashion using an image analysing system ($n = 3$ for each group). Values are means ± S.E.M. * $P < 0.05$ compared with control (DMSO); ** $P < 0.05$ compared with ONO-1301 alone.

Effect of ONO-1301 on angiogenesis in ischaemic myocardium

Anti-CD31 immunostaining revealed that SR-ONO significantly increased capillary density in the ischaemic border zone at 7 days after MI (Figure 4A). The angiogenic effect of SR-ONO was partially abrogated by a neutralizing anti-(mouse VEGF) antibody (Figure 4B), suggesting that ONO-1301 augmented angiogenesis, at least in part, via the up-regulation of VEGF.




Figure 3 Up-regulation of HGF and VEGF expression by SR-ONO

(A) The releasing rate of the ONO-1301–PLGA complex in 0.2% Tween 80/sodium phosphate buffer was determined by measuring residual ONO-1301 in the pellets. (B) The effect of ONO-1301, PLGA and SR-ONO on growth factor secretion. ONO-1301 (1 μmol/l), PLGA (9 μg/ml) or SR-ONO (equivalent to 1 μmol/ml ONO-1301) were added to NHDFs. Supernatants were harvested after 72 h and HGF and VEGF concentrations were determined. * $P < 0.05$. (C) Immediately after coronary ligation, 2 mg of SR-ONO was injected directly into the myocardium ($n = 5$). PLGA (2 mg) containing no ONO-1301 was injected as a control ($n = 5$). Total RNA was isolated at 7 days and RT-PCR was performed. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Effect of ONO-1301 on LV dilatation and survival after MI

LV function was evaluated by echocardiography at 0, 1 and 28 days after MI (Figure 5A). SR-ONO significantly attenuated LV remodelling at 28 days after MI, as determined by increased LVEDD and LVESD (Figure 5B). The survival rate up to 2 weeks after MI was significantly improved by SR-ONO ($P < 0.05$; Figure 6A). The beneficial effects of ONO-1301 were abrogated by administration of an anti-VEGF antibody (Figure 6B).




Figure 4 Increased capillary density at the border zone by ONO-1301 at 7 days after MI

(A) Capillary density at border zone at 7 days after treatment with vehicle and SR-ONO alone or in combination with a neutralizing anti-(human VEGF) antibody (SR-ONO + α VEGF). Endothelial cells were visualized using an anti-CD31 antibody and avidin–biotin and Vector Red chromogenic substrate, followed by counterstaining with haematoxylin. Magnification, $\times 200$. (B) Capillaries were identified by positive staining for anti-CD31 antibody and morphology ($n = 5$ for each group). The number of capillaries/mm² was counted in regions with transversely sectioned myocytes in the border (peri-infarct) zone. Three or four fields in the border zone per section were analysed in each mouse (a total of approx. 10–12 fields/heart) at $\times 200$ magnification. Values are means \pm S.E.M. * $P < 0.01$ compared with vehicle; ** $P < 0.05$ compared with SR-ONO.

DISCUSSION

In the present study, we have demonstrated that ONO-1301 induced the production of endogenous HGF and VEGF *in vitro* and *in vivo*. Injection of SR-ONO augmented angiogenesis in ischaemic myocardium and prevented LV enlargement. ONO-1301 also significantly improved survival after MI. The beneficial effects of ONO-1301 were abrogated by administration of a neutralizing antibody against VEGF.

Therapeutic angiogenesis has emerged as a promising strategy to treat ischaemic diseases. Administration of angiogenic growth factors as proteins or genes enhances collateral formation; however, previous studies have suggested that new vessels regenerated by the overexpression of a single growth factor are not fully functional [33,34], suggesting that a combination of several cytokines are required to regenerate physiological collateral arteries [7,35]. It has been reported that transplantation of bone marrow cells or circulating progenitor cells promotes new vessel formation in ischaemic tissues [3,36,37]. Bone-marrow-derived cells accumulate around growing collateral arteries with expression of several growth factors and chemokines [4,38]. It was

hypothesized that bone-marrow-derived cells promote vascular growth not only by incorporating into vessel walls, but also by secreting several cytokines [4,5]. It is likely that an increase in the local concentration of growth factors at the site of ischaemia would favour collateral formation. Therefore stimulation of local residual cells to produce growth factors could be an alternative strategy to supply growth factors to the site of new vessel formation. In fact, it has been reported that cell transplantation stimulates ischaemic muscle to secrete angiogenic cytokines [39].

It has been shown that PGs regulate HGF expression from cultured cells [8,40]. HGF production was transcriptionally activated by PGE₁ and PGI₂, but only slightly by PGE₂ and PGD₂, in cultured human skin fibroblasts and smooth muscle cells [8,40]. In addition, administration of PGE₁ increased circulating HGF levels in patients with peripheral arterial disease [11]. It has been suggested that the generation of HGF is induced through a cAMP-mediated pathway [41], and a cAMP-responsive element consensus sequence has been located in the promoter region of the HGF gene [32]. HGF induces VEGF expression in smooth muscle cells [42,43] and keratinocytes [44], and Sakurai et al.




Figure 5 Amelioration of LV dilation by SR-ONO

Echocardiographic studies were performed under anaesthesia before surgery (pre) and at 1 and 28 days after MI ($n = 8$ for each group), and LVEDD and LVESD were measured. (A) Representative M-mode echocardiograms obtained from mice treated with vehicle and SR-ONO at 28 days after MI. AW, LV anterior wall; PW, LV posterior wall. (B) Quantification of LVEDD and LVESD in mice treated with vehicle or SR-ONO for up to 28 days after MI. Values are means \pm S.E.M., $n = 8$ for each group. * $P < 0.05$ compared with vehicle at day 28.

[45] have shown that PGs stimulated retinal capillary pericyte proliferation with the induction of *c-fos* mRNA, phosphorylation of CREB (cAMP-response-element-binding protein) and increased expression of VEGF. Induction of VEGF by PGs was almost completely blocked by SQ22536, an adenylate cyclase inhibitor, suggesting that HGF production via the cAMP pathway is the major signalling pathway for the induction of VEGF mRNA by PGs. Thus local administration of PGs appears to effectively induce the production of HGF by local residual cells. HGF subsequently up-regulates VEGF. In the present study, ONO-1301, a synthetic non-prostanoid prostacyclin agonist, successfully up-regulated the expression of VEGF and HGF *in vitro* and *in vivo*. The effect of ONO-1301 was mimicked by a cAMP analogue or cAMP-elevating reagent and was inhibited by a cAMP inhibitor, suggesting that cAMP mediates the beneficial effect of ONO-1301, at least in part.

The prostanoid structure in prostacyclin and its analogues is subjected to metabolism by 15-hydroxyPG dehydrogenase. A phase I clinical trial investigating the oral administration of ONO-1301 has been stopped due




Figure 6 Kaplan-Meier survival analysis after MI in mice treated with vehicle or SR-ONO

MI was induced in 8–10-week-old male CD-1 mice and, immediately after ligation, vehicle (2 mg of PLGA microspheres) or SR-ONO (2 mg) was injected directly into the ischaemic myocardium. In (B), a neutralizing anti-(mouse VEGF) antibody (α VEGF Ab; 0.0025 μ g/kg of body weight) or normal goat IgG (0.025 μ g/kg of body weight) was administered intraperitoneally at 0, 3, 5 and 7 days. (A) The percentage of surviving mice treated with vehicle ($n = 31$) or SR-ONO ($n = 29$). (B) The percentage of surviving mice treated with vehicle ($n = 22$), SR-ONO + normal Ig ($n = 27$) or SR-ONO + α VEGF ($n = 30$). The difference between the groups was tested by the log-rank test.

to a high incidence of diarrhoea (Y. Sakai, unpublished work), possibly due to stimulation of gastrointestinal cells. Systemic administration of ONO-1301 also caused hypotension in mice and rats (Y. Sakai, unpublished work). To overcome these potential side effects caused by oral administration of ONO-1301, we generated SR-ONO with PLGA. PLGA can be gradually absorbed without tissue damage. We did not observe vasodilatation or hypotension, which was reported following systemic administration of a high dose of prostacyclin [46], its analogues or ONO-1301 (Y. Sakai, unpublished work).

Thus SR-ONO appears to enable ONO-1301 to be delivered locally and chronically at the site of ischaemia with minimum adverse systemic effects. For therapeutic use, it would be feasible to optimize the size of the microspheres, the time of drug release and the content of ONO-1301.

In ischaemic hearts, a slight up-regulation of VEGF was observed, which was significantly enhanced by SR-ONO. In contrast, HGF was constitutively expressed by non-ischaemic myocardium and was down-regulated in ischaemic myocardium, a finding consistent with previous studies showing that hypoxic treatment resulted in a significant decrease in local HGF production and an increase in VEGF expression in various cell types [47]. SR-ONO attenuated this ischaemic-induced down-regulation of HGF.

Results from the *in vitro* experiments suggested that growth factors were not induced in endothelial cells, although we could not perform immunohistochemistry to identify which cell types secreted growth factors in the ischaemic heart. It is plausible that growth factors secreted by neighbouring fibroblasts and smooth muscle cells stimulated residual endothelial cells in a paracrine manner.

ONO-1301 prevented LV dilatation with no significant effect on ejection fraction. The preventive effect of ONO-1301 on cardiac remodelling was relatively small when observed at 28 days after MI; however, ONO-1301 significantly increased the capillary density in the ischaemic heart. We also observed that ONO-1301 attenuated myocardial hypertrophy and fibrosis in the intact myocardium (results not shown). Further studies are required to evaluate the long-term effect of ONO-1301 on cardiac function in a chronic myocardial ischaemia model.

In summary, we have demonstrated that ONO-1301 stimulated fibroblasts to secrete angiogenic cytokines. SR-ONO up-regulated HGF and VEGF and promoted angiogenesis in ischaemic mouse hearts. Administration of synthetic small molecules is apparently less invasive than isolation and transplantation of endothelial progenitor cells and/or bone marrow cells. Repeated administration would be easy with a small synthetic molecule, in contrast with autologous bone marrow transplantation that requires bone marrow aspiration. Therefore ONO-1301 might have therapeutic potential in treating ischaemic diseases.

ACKNOWLEDGMENTS

This study was supported, in part, by grants from the Ministry of Education, Culture, Sports, Science and Technology, and the Ministry of Health, Labor and Welfare of Japan. Y.S. is an employee of Ono Pharmaceutical Company Ltd.

REFERENCES

- 1 Freedman, S. and Isner, J. M. (2001) Therapeutic angiogenesis for ischemic cardiovascular disease. *J. Mol. Cell. Cardiol.* **33**, 379–393
- 2 Losordo, D. W. and Dimmeler, S. (2004) Therapeutic angiogenesis and vasculogenesis for ischemic disease: part I: angiogenic cytokines. *Circulation* **109**, 2487–2491
- 3 Khakoo, A. Y. and Finkel, T. (2005) Endothelial progenitor cells. *Annu. Rev. Med.* **56**, 79–101
- 4 Ziegelhoeffer, T., Fernandez, B., Kostin, S. et al. (2004) Bone marrow-derived cells do not incorporate into the adult growing vasculature. *Circ. Res.* **94**, 230–238
- 5 O'Neill, IV T. J., Wamhoff, B. R., Owens, G. K. and Skalak, T. C. (2005) Mobilization of bone marrow-derived cells enhances the angiogenic response to hypoxia without transdifferentiation into endothelial cells. *Circ. Res.* **97**, 1027–1035
- 6 Hughes, G. C., Biswas, S. S., Yin, B. et al. (2004) Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF. *Ann. Thorac. Surg.* **77**, 812–818
- 7 Yamauchi, A., Ito, Y., Morikawa, M. et al. (2003) Pre-administration of angiopoietin-1 followed by VEGF induces functional and mature vascular formation in a rabbit ischemic model. *J. Gene Med.* **5**, 994–1004
- 8 Matsumoto, K., Okazaki, H. and Nakamura, T. (1995) Novel function of prostaglandins as inducers of gene expression of HGF and putative mediators of tissue regeneration. *J. Biochem. (Tokyo)* **117**, 458–464
- 9 Pai, R., Szabo, I. L., Soreghan, B. A., Atay, S., Kawanaka, H. and Tarnawski, A. S. (2001) PGE2 stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. *Biochem. Biophys. Res. Commun.* **286**, 923–928
- 10 Mehrabi, M. R., Serbecic, N., Tamaddon, F. et al. (2002) Clinical and experimental evidence of prostaglandin E1-induced angiogenesis in the myocardium of patients with ischemic heart disease. *Cardiovasc. Res.* **56**, 214–224
- 11 Makino, H., Aoki, M., Hashiya, N. et al. (2004) Increase in peripheral blood flow by intravenous administration of prostaglandin E1 in patients with peripheral arterial disease, accompanied by up-regulation of hepatocyte growth factor. *Hypertens. Res.* **27**, 85–91
- 12 Matsumoto, K., Morishita, R., Tomita, N. et al. (2002) Impaired endothelial dysfunction in diabetes mellitus rats was restored by oral administration of prostaglandin I2 analogue. *J. Endocrinol.* **175**, 217–223
- 13 Coker, S. J., Parratt, J. R., Ledingham, I. M. and Zeitlin, I. J. (1981) Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. *Nature* **291**, 323–324
- 14 Johnson, III, G., Furlan, L. E., Aoki, N. and Lefer, A. M. (1990) Endothelium and myocardial protecting actions of taprostene, a stable prostacyclin analogue, after acute myocardial ischemia and reperfusion in cats. *Circ. Res.* **66**, 1362–1370
- 15 de Deckere, E. A., Nugteren, D. H. and Ten Hoor, F. (1977) Prostacyclin is the major prostaglandin released from the isolated perfused rabbit and rat heart. *Nature* **268**, 160–163
- 16 Pola, R., Gaetani, E., Flex, A. et al. (2004) Comparative analysis of the *in vivo* angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors. *J. Mol. Cell. Cardiol.* **36**, 363–370
- 17 Hayashi, K., Nagamatsu, T., Oka, T. and Suzuki, Y. (1997) Modulation of anti-glomerular basement membrane nephritis in rats by ONO-1301, a non-prostanoid prostaglandin I2 mimetic compound with inhibitory activity against thromboxane A2 synthase. *Jpn J. Pharmacol.* **73**, 73–82

- 18 Rudd, J. A., Qian, Y., Tsui, K. K. and Jones, R. L. (2000) Non-prostanoid prostacyclin mimetics as neuronal stimulants in the rat: comparison of vagus nerve and NANC innervation of the colon. *Br. J. Pharmacol.* **129**, 782–790
- 19 Murakami, S., Nagaya, N., Itoh, T. et al. (2006) Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **290**, L59–L65
- 20 Imawaka, H. and Sugiyama, Y. (1998) Kinetic study of the hepatobiliary transport of a new prostaglandin receptor agonist. *J. Pharmacol. Exp. Ther.* **284**, 949–957
- 21 Shiomi, T., Tsutsui, H., Hayashidani, S. et al. (2002) Pioglitazone, a peroxisome proliferator-activated receptor- γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. *Circulation* **106**, 3126–3132
- 22 Bishop, E. T., Bell, G. T., Bloor, S., Broom, I. J., Hendry, N. F. and Wheatley, D. N. (1999) An *in vitro* model of angiogenesis: basic features. *Angiogenesis* **3**, 335–344
- 23 Cao, B., Su, Y., Oskarsson, M. et al. (2001) Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 7443–7448
- 24 Stiffey-Wilusz, J., Boice, J. A., Ronan, J., Fletcher, A. M. and Anderson, M. S. (2001) An *ex vivo* angiogenesis assay utilizing commercial porcine carotid artery: modification of the rat aortic ring assay. *Angiogenesis* **4**, 3–9
- 25 Michael, L. H., Entman, M. L., Hartley, C. J. et al. (1995) Myocardial ischemia and reperfusion: a murine model. *Am. J. Physiol. Heart Circ. Physiol.* **269**, H2147–H2154
- 26 Tanaka, K., Sata, M., Hirata, Y. and Nagai, R. (2003) Diverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuries. *Circ. Res.* **93**, 783–790
- 27 Youn, H. J., Rokosh, G., Lester, S. J., Simpson, P., Schiller, N. B. and Foster, E. (1999) Two-dimensional echocardiography with a 15-MHz transducer is a promising alternative for *in vivo* measurement of left ventricular mass in mice. *J. Am. Soc. Echocardiogr.* **12**, 70–75
- 28 Sata, M., Nishimatsu, H., Suzuki, E. et al. (2001) Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia. *FASEB J.* **15**, 2530–2532
- 29 Scherrer-Crosbie, M., Ullrich, R., Bloch, K. D. et al. (2001) Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. *Circulation* **104**, 1286–1291
- 30 Barandon, L., Couffinhal, T., Ezan, J. et al. (2003) Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA. *Circulation* **108**, 2282–2289
- 31 Shoji, M., Sata, M., Fukuda, D. et al. (2004) Temporal and spatial characterization of cellular constituents during neointimal hyperplasia after vascular injury: Potential contribution of bone-marrow-derived progenitors to arterial remodeling. *Cardiovasc. Pathol.* **13**, 306–312
- 32 Nakano, N., Morishita, R., Moriguchi, A. et al. (1998) Negative regulation of local hepatocyte growth factor expression by angiotensin II and transforming growth factor- β in blood vessels: potential role of HGF in cardiovascular disease. *Hypertension* **32**, 444–451
- 33 Lee, R. J., Springer, M. L., Blanco-Bose, W. E., Shaw, R., Ursell, P. C. and Blau, H. M. (2000) VEGF gene delivery to myocardium: deleterious effects of unregulated expression. *Circulation* **102**, 898–901
- 34 Carmeliet, P. (2000) VEGF gene therapy: stimulating angiogenesis or angioma-genesis? *Nat. Med.* **6**, 1102–1103
- 35 Thurston, G., Suri, C., Smith, K. et al. (1999) Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. *Science* **286**, 2511–2514
- 36 Murohara, T., Ikeda, H., Duan, J. et al. (2000) Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. *J. Clin. Invest.* **105**, 1527–1536
- 37 Kalka, C., Masuda, H., Takahashi, T. T. et al. (2000) Transplantation of *ex vivo* expanded endothelial progenitor cells for therapeutic neovascularization. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 3422–3427
- 38 Urbich, C. and Dimmeler, S. (2004) Endothelial progenitor cells: characterization and role in vascular biology. *Circ. Res.* **95**, 343–353
- 39 Tateno, K., Minamino, T., Toko, H. et al. (2006) Critical roles of muscle-secreted angiogenic factors in therapeutic neovascularization. *Circ. Res.* **98**, 1194–1202
- 40 Morishita, R., Nakamura, S., Nakamura, Y. et al. (1997) Potential role of an endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes. *Diabetes* **46**, 138–142
- 41 Matsunaga, T., Gohda, E., Takebe, T. et al. (1994) Expression of hepatocyte growth factor is up-regulated through activation of a cAMP-mediated pathway. *Exp. Cell Res.* **210**, 326–335
- 42 Van Belle, E., Witzensbichler, B., Chen, D. et al. (1998) Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. *Circulation* **97**, 381–390
- 43 Xin, X., Yang, S., Ingle, G. et al. (2001) Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis *in vitro* and *in vivo*. *Am. J. Pathol.* **158**, 1111–1120
- 44 Gille, J., Khalik, M., Konig, V. and Kaufmann, R. (1998) Hepatocyte growth factor/scatter factor (HGF/SF) induces vascular permeability factor (VPF/VEGF) expression by cultured keratinocytes. *J. Invest. Dermatol.* **111**, 1160–1165
- 45 Sakurai, S., Alam, S., Pagan-Mercado, G. et al. (2002) Retinal capillary pericyte proliferation and c-Fos mRNA induction by prostaglandin D2 through the cAMP response element. *Invest. Ophthalmol. Vis. Sci.* **43**, 2774–2781
- 46 Skrinska, V. A., Lucas, F. V., Chisolm, G. M. and Hesse, B. L. (1986) Intravenous administration of prostacyclin in rabbits: elimination kinetics and blood pressure response. *J. Lab. Clin. Med.* **107**, 187–193
- 47 Hayashi, S., Morishita, R., Nakamura, S. et al. (1999) Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells. *Circulation* **100**, II301–II308